ArticleClinical transplantation2026
Reduction in Donor-Derived Cell-Free DNA After Rejection Treatment is Associated With Improved Long Term Allograft Function.
Article in Clinical transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reduction in Donor-Derived Cell-Free DNA After Rejection Treatment is Associated With Improved Long Term Allograft Function.Clinical transplantation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Donor derived cell-free DNA (dd-cfDNA) has become a useful biomarker for monitoring of kidney transplant rejection, however utilization after rejection is not well established. We conducted a retrospective cohort study of 64 kidney transplant recipients (KTRs) with biopsy-proven rejection and concomitant dd-cfDNA monitoring. The primary outcome was to examine the relationship between changes in dd-cfDNA and allograft function after rejection. Secondary outcomes included the effect of a ≥61% dd-cfDNA reduction on eGFR and proteinuria, and impact of persistently elevated dd-cfDNA. The percent change in dd-cfDNA from rejection to 6 months post-rejection and 1-year post-rejection was negatively correlated with eGFR change at 1, 2, and 3 years. No correlation was seen with dd-cfDNA values at 1 month. KTRs with at least 61% decrease in dd-cfDNA from rejection to 1-year post-rejection showed improvement in eGFR at 1, 2, and 3 years. KTRs with persistently elevated dd-cfDNA showed significantly worse change in eGFR to all time points compared to those without. Incidence of proteinuria at 1, 2, and 3 years trended lower in KTRs with ≥61% decrease in dd-cfDNA. dd-cfDNA was negatively correlated with eGFR, primarily at 6-12 months post-rejection. In conclusion, persistently elevated dd-cfDNA correlates with worse longitudinal changes in eGFR through 3 years post-rejection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.